Regulation 3

SCHEDULE 1 U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

1.  The following substances and products, namely - U.K.

(a) Bufotenine

• Cannabinol

• Cannabinol derivatives not being dronabinol or its stereoisomers

• Cannabis [F1 (not being the substance specified in paragraph 5 of Part 1 of Schedule 4)] and cannabis resin

• Cathinone

• Coca leaf

• Concentrate of poppy-straw

• [F2 [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone]

• [F2 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol]

• Eticyclidine

• Etryptamine

• [F3 Fungus (of any kind) which contains psilocin or an ester of psilocin]

• [F4 [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate]

• [F4 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol]

• [F5 Khat]

• Lysergamide

• Lysergide and otherN-alkyl derivatives of lysergamide

• Mescaline

• Methcathinone

• F6 ...

• Psilocin

• Raw opium

• Rolicyclidine

• Tenocyclidine

• [F7 (6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52)]

• 4-Bromo-2,5-dimethoxy-a-methylphenethylamine

• [F8 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)]

• [F9 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)]

• [F9 (6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)]

• [F9 (6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)]

• [F9 (6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)]

• N,N-Diethyltryptamine

• [F10 2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol]

• [F11 2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone (LSZ)]

• N,N-Dimethyltryptamine

• 2,5-Dimethoxy-a,4-dimethylphenethylamine

• N-Hydroxy-tenamphetamine

• 4-Methyl-aminorex

• [F12 4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)]

[F13 (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;]

(c) the following phenethylamine derivatives, namely—

• Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

• 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

• Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 4-Bromo-b,2,5-trimethoxyphenethylamine

• N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

• Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

• 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

• 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

• N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

• a,a-Dimethyl-3,4-methylenedioxyphenethylamine

• a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

• Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

• 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

• 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• 2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• b-Methoxy-3,4-methylenedioxyphenethylamine

• 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

• 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

• 2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol

• a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

• N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• a-Methyl-4-(methylthio)phenethylamine

• b,3,4,5-Tetramethoxyphenethylamine

• b,2,5-Trimethoxy-4-methylphenethylamine

(d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

(e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -

(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi) by replacement of theN-propionyl group by another acyl group;

(f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—

(i) by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v) by formation of an N-oxide or of a quaternary base.

[F14 (g) 1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—

(i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

(ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;

[F15 (h) Any compound structurally derived from 3–(1–naphthoyl)indole, 3-(2-naphthoyl)indole, 1H–indol–3–yl–(1–naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(i) Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(j) Any compound structurally derived from 1–(1–naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3–position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(k) Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.]

(l) any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.]

[F16 (la) Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

(lb) Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.

(lc) Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.]

[F17 (m) Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say—

(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii) by substitution at the 3–position with an alkyl substituent;

(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]

[F18 (n) Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1‑position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say—

(i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii) by substitution at the 3–position with an alkyl substituent;

(iii) by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2‑amino nitrogen atom in a cyclic structure.]

[F19 (o) Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,

(i) by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;

(ii) by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;

(iii) by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.]

[F20 (p) 1-Phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine or tiletamine) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,

(i) by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups;

(ii) by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent;

(iii) by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;

(iv) by replacement of the phenyl ring with a thienyl ring.]

[F21 (q) Any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2,5-dimethoxy-α,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph (c) or (d) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent;

(r) Any compound (not being a compound for the time being specified in sub- paragraph (c) above) structurally derived from 1-benzofuran, 2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents.]

Textual Amendments

F1 Words in Sch. 1 para. 1(a) inserted (10.4.2013) by The Misuse of Drugs (Amendment No. 2) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/625), regs. 1(1), 6

F2 Words in Sch. 1 para. 1(a) inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(1)(a)(i)

F3 Words in Sch. 1 para. 1(a) inserted (18.7.2005) by The Misuse of Drugs (Amendment) (No. 2) Regulations 2005 (S.I. 2005/1653), regs. 1, 2(3)

F4 Words in Sch. 1 para. 1(a) inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(1)(a)(ii)

F5 Word in Sch. 1 para. 1(a) inserted (24.6.2014) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1377), regs. 1(1), 3

F6 Word in Sch. 1 para. 1(a) omitted (28.3.2011) by virtue of The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2011 (S.I. 2011/448), regs. 1(1), 4

F7 Words in Sch. 1 para. 1(a) inserted (7.1.2015) by The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 3(a)

F8 Words in Sch. 1 para. 1(a) inserted (11.3.2015) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2015 (S.I. 2015/231), regs. 1(1), 3(a)

F9 Words in Sch. 1 para. 1(a) inserted (7.1.2015) by The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 3(b)

F10 Words in Sch. 1 para. 1(a) inserted (26.2.2013) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/176), regs. 1(1), 3

F11 Words in Sch. 1 para. 1(a) inserted (7.1.2015) by The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 3(c)

F12 Words in Sch. 1 para. 1(a) inserted (11.3.2015) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2015 (S.I. 2015/231), regs. 1(1), 3(b)

F13 Sch. 1 para. 1(b) substituted (7.1.2015) by The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 4

F14 Sch. 1 para. 1(g)-(l) inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(1)(b)

F15 Sch. 1 para. 1(h)-(k) substituted (26.2.2013) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/176), regs. 1(1), 4

F16 Sch. 1 para. 1(la)-(lc) inserted (26.2.2013) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/176), regs. 1(1), 5

F17 Sch. 1 para. 1(m) inserted (16.4.2010) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2010 (S.I. 2010/1144), regs. 1(1), 3(b)

F18 Sch. 1 para. 1(n) inserted (23.7.2010) by The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2010 (S.I. 2010/1799), regs. 1(1), 3

F19 Sch. 1 para. 1(o) inserted (13.6.2012) by The Misuse of Drugs (Amendment No.3) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/1311), regs. 1(1), 3

F20 Sch. 1 para. 1(p) inserted (26.2.2013) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/176), regs. 1(1), 6

F21 Sch. 1 para. 1(q)(r) inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 3

2.  Any stereoisomeric form of a substance specified in paragraph 1. U.K.

[F22 3.   Any ester or ether of a substance specified in paragraph 1 (not being 2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol) or paragraph 2.] U.K.

Textual Amendments

F22 Sch. 1 para. 3 substituted (26.2.2013) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/176), regs. 1(1), 7

4.  Any salt of a substance specified in any of paragraphs 1 to 3. U.K.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 2 U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 21, 23, 26 AND 27

1.  The following substances and products, namely— U.K.

• Acetorphine

• Alfentanil

• Allylprodine

• Alphacetylmethadol

• Alphameprodine

• Alphamethadol

• Alphaprodine

• [F23 Amineptine]

• Anileridine

• Benzethidine

• Benzylmorphine (3-benzylmorphine)

• Betacetylmethadol

• Betameprodine

• Betamethadol

• Betaprodine

• Bezitramide

• Carfentanil

• Clonitazene

• Cocaine

• Desomorphine

• Dextromoramide

• Diamorphine

• Diampromide

• Diethylthiambutene

• Difenoxin

• Dihydrocodeinone O-carboxymethyloxime

• [F24 Dihydroetorphine]

• Dihydromorphine

• Dimenoxadole

• Dimepheptanol

• Dimethylthiambutene

• Dioxaphetyl butyrate

• Diphenoxylate

• Dipipanone

• Dronabinol

• Drotebanol

• Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine

• Ethylmethylthiambutene

• Etonitazene

• Etorphine

• Etoxeridine

• Fentanyl

• Furethidine

• Hydrocodone

• Hydromorphinol

• Hydromorphone

• [F25 4-Hydroxy-n-butyric acid]

• Hydroxypethidine

• Isomethadone

• Ketobemidone

• Levomethorphan

• Levomoramide

• Levophenacylmorphan

• Levorphanol

• [F26 Lisdexamphetamine]

• Lofentanil

• Medicinal opium

• Metazocine

• Methadone

• Methadyl acetate

• Methyldesorphine

• Methyldihydromorphine (6-methyldihydromorphine)

• Metopon

• Morpheridine

• Morphine

• Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives

• Myrophine

• [F27 Nabilone]

• Nicomorphine

• Noracymethadol

• Norlevorphanol

• Normethadone

• Normorphine

• Norpipanone

• [F28 Oripavine]

• Oxycodone

• Oxymorphone

• Pethidine

• Phenadoxone

• Phenampromide

• Phenazocine

• Phencyclidine

• Phenomorphan

• Phenoperidine

• Piminodine

• Piritramide

• Proheptazine

• Properidine

• Racemethorphan

• Racemoramide

• Racemorphan

• [F29 Remifentanil]

• Sufentanil

• [F30 Tapentadol]

• Thebacon

• Thebaine

• Tilidate

• Trimeperidine

• Zipeprol

• 4-Cyano-2-dimethylamino-4,4-diphenylbutane

• 4-Cyano-1-methyl-4-phenylpiperidine

• 2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid

• a-Methylphenethylhydroxylamine

• 1-Methyl-4-phenylpiperidine-4-carboxylic acid

• 4-Phenylpiperidine-4-carboxylic acid ethyl ester

Textual Amendments

F23 Word in Sch. 2 para. 1 inserted (28.3.2011) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2011 (S.I. 2011/448), regs. 1(1), 5(a)

F24 Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(a)

F25 Words in Sch. 2 para. 1 inserted (7.1.2015) by The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 5

F26 Word in Sch. 2 para. 1 inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 4

F27 Word in Sch. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(2)(a)

F28 Word in Sch. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(2)(b)

F29 Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(b)

F30 Word in Sch. 2 para. 1 inserted (28.3.2011) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2011 (S.I. 2011/448), regs. 1(1), 5(b)

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan. U.K.

3.  Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6. U.K.

4.  Any salt of a substance specified in any of paragraphs 1 to 3. U.K.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5. U.K.

6.  The following substances and products, namely— U.K.

Acetyldihydrocodeine	Methaqualone
Amphetamine	Methylamphetamine
Codeine	Methylphenidate
Dextropropoxyphene	Nicocodine
Dihydrocodeine	Nicodicodine (6-nicotinoyldihydrocodeine)
Ethylmorphine (3-ethylmorphine)	Norcodeine
Fenethylline	Phenmetrazine
Glutethimide	Pholcodine
Lefetamine	Propiram
Mecloqualone	Quinalbarbitone

7.  Any stereoisomeric form of a substance specified in paragraph 6. U.K.

8.  Any salt of a substance specified in paragraph 6 or 7. U.K.

9.  Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 3 U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15 (EXCEPT TEMAZEPAM), 16, 18, 22, 23, 24, 26 AND 27

1.  The following substances, namely— U.K.

(a)  

• Benzphetamine

• [F31 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one]

• Buprenorphine

• Cathine

• Chlorphentermine

• Diethylpropion

• Ethchlorvynol

• Ethinamate

• Flunitrazepam

• Mazindol

• Mephentermine

• Meprobamate

• Methylphenobarbitone

• Methyprylone

• [F32 Midazolam]

• Pentazocine

• Phendimetrazine

• Phentermine

• Pipradrol

• Temazepam

• [F33 Tramadol]

(b) any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

Textual Amendments

F31 Words in Sch. 3 para. 1(a) inserted (13.6.2012) by The Misuse of Drugs (Amendment No.3) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/1311), regs. 1(1), 4

F32 Word in Sch. 3 para. 1(a) inserted (1.1.2008) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(14)

F33 Word in Sch. 3 para. 1(a) inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 5

[F34 2.   Any stereoisomeric form of a substance specified in paragraph 1 or 3 not being phenylpropanolamine. U.K.

Textual Amendments

F34 Sch. 3 paras. 2-5 substituted for Sch. 3 paras. 2-4 (13.6.2012) by The Misuse of Drugs (Amendment No.3) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/1311), regs. 1(1), 5

3.   Any ester or ether of pipradrol. U.K.

Textual Amendments

F34 Sch. 3 paras. 2-5 substituted for Sch. 3 paras. 2-4 (13.6.2012) by The Misuse of Drugs (Amendment No.3) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/1311), regs. 1(1), 5

4.   Any salt of a substance specified in any of paragraphs 1 to 3. U.K.

Textual Amendments

F34 Sch. 3 paras. 2-5 substituted for Sch. 3 paras. 2-4 (13.6.2012) by The Misuse of Drugs (Amendment No.3) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/1311), regs. 1(1), 5

5.   Any preparation or other product containing a substance specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.] U.K.

Textual Amendments

F34 Sch. 3 paras. 2-5 substituted for Sch. 3 paras. 2-4 (13.6.2012) by The Misuse of Drugs (Amendment No.3) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/1311), regs. 1(1), 5

Regulation 3

SCHEDULE 4 U.K.

PART I U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances and products, namely— U.K.

• Alprazolam

• Aminorex

• Bromazepam

• Brotizolam

• Camazepam

• Chlordiazepoxide

• [F35 1–(3–chlorophenyl)piperazine]

• [F35 1–(3–chlorophenyl)–4–(3–chloropropyl)piperazine]

• Clobazam

• Clonazepam

• Clorazepic acid

• Clotiazepam

• Cloxazolam

• Delorazepam

• Diazepam

• Estazolam

• Ethyl loflazepate

• Fencamfamin

• Fenproporex

• Fludiazepam

• Flurazepam

• Halazepam

• Haloxazolam

• F36 ...

• [F37 Ketamine]

• Ketazolam

• Loprazolam

• Lorazepam

• Lormetazepam

• Medazepam

• Mefenorex

• Mesocarb

• F38 ...

• Nimetazepam

• Nitrazepam

• Nordazepam

• Oxazepam

• Oxazolam

• Pemoline

• Pinazepam

• Prazepam

• Pyrovalerone

• Tetrazepam

• Triazolam

• N-Ethylamphetamine

• [F39 Zaleplon]

• [F40 Zolpidem]

• [F41 Zopiclone]

Textual Amendments

F35 Words in Sch. 4 Pt. 1 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(3)

F36 Words in Sch. 4 Pt. 1 para. 1 omitted (7.1.2015) by virtue of The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 6

F37 Word in Sch. 4 Pt. 1 para. 1 inserted (1.1.2006) by The Misuse of Drugs (Amendment) (No. 3) Regulations 2005 (S.I. 2005/3372), regs. 1, 2

F38 Word in Sch. 4 Pt. 1 para. 1 omitted (1.1.2008) by virtue of The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(13)

F39 Word in Sch. 4 Pt. 1 para. 1 inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 6(a)

F40 Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)

F41 Word in Sch. 4 Pt. 1 para. 1 inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 6(b)

2.  Any stereoisomeric form of a substance specified in paragraph 1. U.K.

3.  Any salt of a substance specified in paragraph 1 or 2. U.K.

4.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5. U.K.

[F42 5.   A liquid formulation— U.K.

(a) containing a botanical extract of cannabis—

(i) with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and

(ii) where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,

(b) which is dispensed through a metered dose pump as a mucosal mouth spray, and

(c) which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16^th June 2010]

Textual Amendments

F42 Sch. 4 Pt. 1 para. 5 inserted (10.4.2013) by The Misuse of Drugs (Amendment No. 2) (England, Wales and Scotland) Regulations 2013 (S.I. 2013/625), regs. 1(1), 7

PART II U.K. [F43 Controlled Drugs Excepted From the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27]

Textual Amendments

F43 Sch. 4 Pt. 2 heading substituted (23.4.2012) by The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/973), regs. 1(1), 15

1.  The following substances, namely— U.K.

• [F44 5α–Androstane–3,17–diol]

• [F44 Androst-4-ene-3,17-diol]

• [F44 1–Androstenediol]

• [F44 1–Androstenedione]

• [F45 4-Androstene-3, 17-dione]

• [F46 5–Androstenedione]

• [F45 5-Androstene-3, 17 diol]

• Atamestane

• Bolandiol

• Bolasterone

• Bolazine

• Boldenone

• [F47 Boldione]

• Bolenol

• Bolmantalate

• Calusterone

• 4-Chloromethandienone

• Clostebol

• [F48 Danazol]

• [F48 Desoxymethyltestosterone]

• Drostanolone

• Enestebol

• Epitiostanol

• Ethyloestrenol

• Fluoxymesterone

• Formebolone

• Furazabol

• [F49 Gestrinone]

• [F49 3–Hydroxy–5α–androstan–17–one]

• Mebolazine

• Mepitiostane

• Mesabolone

• Mestanolone

• Mesterolone

• Methandienone

• Methandriol

• Methenolone

• Methyltestosterone

• Metribolone

• Mibolerone

• Nandrolone

• [F50 19–Norandrostenedione]

• [F51 19-Nor-4-Androstene-3, 17-dione]

• [F51 19-Nor-5-Androstene-3, 17 diol]

• [F52 19–Norandrosterone]

• Norboletone

• Norclostebol

• Norethandrolone

• [F53 19–Noretiocholanolone]

• Ovandrotone

• Oxabolone

• Oxandrolone

• Oxymesterone

• Oxymetholone

• Prasterone

• Propetandrol

• [F54 Prostanozol]

• Quinbolone

• Roxibolone

• Silandrone

• Stanolone

• Stanozolol

• Stenbolone

• Testosterone

• [F55 Tetrahydrogestrinone]

• Thiomesterone

• Trenbolone

Textual Amendments

F44 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(i)

F45 Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)

F46 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(ii)

F47 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(iii)

F48 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(iv)

F49 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(v)

F50 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(vi)

F51 Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)

F52 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(vii)

F53 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(viii)

F54 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(ix)

F55 Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(x)

2.  Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say - U.K.

(a) by further substitution at position 17 by a methyl or ethyl group;

(b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(d) by fusion of ring A with a heterocyclic system.

3.  Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule. U.K.

4.  The following substances, namely— U.K.

• Chorionic Gonadotrophin (HCG)

• Clenbuterol

• Non-human chorionic gonadotrophin

• Somatotropin

• Somatrem

• Somatropin

• [F56 Zeranol]

• [F56 Zilpaterol]

Textual Amendments

F56 Words in Sch. 4 Pt. 2 para. 4 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(b)

5.  Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule. U.K.

6.  Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule. U.K.

7.  Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 5 U.K. CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON IMPORTATION, EXPORTATION AND POSSESSION AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26

1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations. U.K.

(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.

F57 2.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . U.K.

Textual Amendments

F57 Sch. 5 para. 2 revoked (14.11.2005) by The Misuse of Drugs and the Misuse of Drugs (Supply to Addicts) (Amendment) Regulations 2005 (S.I. 2005/2864), regs. 1(1), 13

3.  Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health. U.K.

4.  Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations. U.K.

5.  Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin. U.K.

6.  Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate. U.K.

7.  Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose. U.K.

8.  Any powder of ipecacuanha and opium comprising— U.K.

• 10% opium, in powder,

• 10% ipecacuanha root, in powder, well mixed with

• 80% of any other powdered ingredient containing no controlled drug.

9.  Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug. U.K.

Regulation 19

F58 SCHEDULE 6 U.K. FORM OF REGISTER

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

F58 Sch. 6 revoked (1.2.2008) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(4)(b), 4(15)

Regulation 28

SCHEDULE 7 U.K. REGULATIONS REVOKED

Regulations revoked	References
The Misuse of Drugs Regulations 1985	S.I. 1985/2066
The Misuse of Drugs (Amendment) Regulations 1986	S.I. 1986/2330
The Misuse of Drugs (Amendment) Regulations 1988	S.I. 1988/916
The Misuse of Drugs (Amendment) Regulations 1989	S.I. 1989/1460
The Misuse of Drugs (Amendment) Regulations 1990	S.I. 1990/2630
The Misuse of Drugs (Amendment) Regulations 1995	S.I. 1995/2048
The Misuse of Drugs (Amendment No. 2) Regulations 1995	S.I. 1995/3244
The Misuse of Drugs (Amendment) Regulations 1996	S.I. 1996/1597
The Misuse of Drugs (Amendment) Regulations 1998	S.I. 1998/882
The Misuse of Drugs (Amendment) Regulations 1999	S.I. 1999/1404

[F60 Regulations 6(2), 8(8), 9(8) and 10(2)]

[F59 SCHEDULE 8 U.K.

Textual Amendments

F59 Sch. 8 inserted (15.10.2003) by The Misuse of Drugs (Amendment) (No. 3) Regulations 2003 (S.I. 2003/2429), reg. 1, Sch.

F60 Sch. 8 reference note substituted (23.4.2012) by The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/973), regs. 1(1), 16

1.   Any of the following persons may supply or administer a specified controlled drug under a patient group direction, namely— U.K.

(a) a person who holds a certificate of proficiency in ambulance paramedic skills issued by, or with the approval of, the Secretary of State, or a person who is a F61 ... registered paramedic;

F62 (b) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(c) a registered midwife;

[F63 (d) a registered optometrist;

(e) a registered chiropodist;

(f) a registered orthoptist;

(g) a registered physiotherapist;

(h) a registered radiographer;]

[F64 (i) a registered occupational therapist;

(j) a registered orthotist and prosthetist;]

[F65 (k) a pharmacist]];

Textual Amendments

F61 Word in Sch. 8 para. 1(a) revoked (16.8.2007) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(1), 4(16)(a)

F62 Sch. 8 para. 1(b) omitted (1.8.2004) by virtue of The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 24(d)

F63 Sch. 8 para. 1(d)-(h) substituted (16.8.2007) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(1), 4(16)(b)

F64 Sch. 8 para. 1(i)(j) inserted (7.7.2006) by The Misuse of Drugs (Amendment No. 2) Regulations 2006 (S.I. 2006/1450), regs. 2(1), 11 (with regs. 12, 13)

F65 Sch. 8 para. 1(k) inserted (23.4.2012) by The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/973), regs. 1(1), 16